MedTrace Logo

Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)

NCT05454787 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-05-27

No results posted yet for this study

Summary

This survey will be conducted to investigate the status of occurrence of the safety specifications set for "Safety specification" in patients who received Ondexxya Intravenous Injection 200 mg. In addition, this survey will be implemented to understand the followings by collecting safety and effectiveness information under actual use conditions.

Conditions

  • Life Threatening Bleeding
  • Factor Xa Inhibitor

Sponsors & Collaborators

Principal Investigators

  • Toshimitsu Tokimoto · Astrazeneca KK

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-02
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05454787 on ClinicalTrials.gov